Prescription Medicine Manufacturers

The thesis

Own research-based drug manufacturers whose commercial franchises fund continued pipeline development, rather than businesses dependent on AI infrastructure spending. Their recent relative strength makes prescription medicines a defensive alternative during the technology drawdown, while Amgen's upcoming earnings provide a near-term execution test. Strong share-price performance already discounts considerable success, so clinical setbacks, patent expirations and pricing pressure remain important